Ectomesenchymoma

Changed by Joachim Feger, 12 Dec 2022
Disclosures - updated 26 Nov 2022: Nothing to disclose

Updates to Article Attributes

Body was changed:

Ectomesenchymomas are biphasic or composite malignant soft tissue tumours with rhabdomyosarcoma resembling parts and neuronal or neuroblastic features.

Terminology

The term ‘gangliorhabdomyosarcoma’ is not recommended anymore.

Epidemiology

Ectomesenchymomas are very rare and usually occur in infants and children ≤ 15 years with a slight male predominance 1-3.

Diagnosis

The diagnosis of ectomesenchymoma is based on histology and immunohistochemistry.

Diagnostic criteria

Diagnostic criteria according to the WHO classification of soft tissue and bone tumours (5th edition)1:

Clinical presentation

The most common presentation is a superficial or deep soft tissue mass or an incidental finding on imaging studies 1.  

Pathology

Ectomesenchymoma features a compound biphasic morphology with mesenchymal components resembling embryonal rhabdomyosarcoma and neuroectodermal or neuroblastic elements 1-3.

Aetiology

The aetiology is unknown 1.

Location

Ectomesenchymomas have been described in the following locations 1-5:

  • pelvis/perineum

  • intraabdominal and retroperitoneum including urogenital organs

  • head and neck region

  • intracranial

Less commonly affected are the extremities and the mediastinum.

Macroscopic appearance

Tumours usually vary widely in size and are multilobulated and encapsulated. They might show features of haemorrhage and/or necrosis and feature a tan to whitish appearance 1.

Microscopic appearance

Ectomesenchymoma feature two histological components:

Immunophenotype

Ectomesenchymoma is a multi phenotypic-phenotypic tumour and immunohistochemistry stains are usually positive for muscle specific-specific actin (MSA), desmin and MYOD1 as well as neuron specificneurone-specific enolase (NSE) synaptophysin, chromogranin A and S100 1,2.

Radiographic features

Imaging findings seem to be a generally non-specific, heterogeneous mass 4,5.

MRI

Magnetic resonance imaging features have been described asare those of a lobular, heterogeneous, partially cystic enhancing-enhancing mass 2,5.

Radiology report

The radiological report should include a description of the following:

  • form, location and size

  • tumour margins and transition zone

  • relations to other organs

  • contact to bones or neurovascular structures

  • associated lymphadenopathy

Treatment and prognosis

Treatment is usually multimodal and based on rhabdomyosarcoma-like management strategies. Superficial: superficial location, smaller tumour size and younger age ≤ 3years≤3 years are favourable factors 1,4.

History and etymology

Initial suggestions regarding the entity ectomesenchymoma were probably made by the American pathologists Samruay Shuangshoti and Martin G Netsky as well as James L. Holimon and William I. Rosenblum in 1971 6,7.

Differential diagnosis

Conditions that can mimic the presentation and/or appearance of ectomesenchymomas also depend on the location of the tumour and include 3-5:

  • -<p><strong>Ectomesenchymomas</strong> are biphasic or composite malignant <a href="/articles/who-classification-of-tumors-of-soft-tissue">soft tissue tumours</a> with rhabdomyosarcoma resembling parts and neuronal or neuroblastic features.</p><h4>Terminology</h4><p>The term ‘gangliorhabdomyosarcoma’ is not recommended anymore.</p><h4>Epidemiology</h4><p>Ectomesenchymomas are very rare and usually occur in infants and children ≤ 15 years with a slight male predominance <sup>1-3</sup>.</p><h4>Clinical presentation</h4><p>The most common presentation is a superficial or deep soft tissue mass or an incidental finding on imaging studies <sup>1</sup>.  </p><h4>Pathology</h4><p>Ectomesenchymoma features a compound biphasic morphology with mesenchymal components resembling <a href="/articles/embryonal-rhabdomyosarcoma">embryonal rhabdomyosarcoma</a> and neuroectodermal or neuroblastic elements <sup>1-3</sup>.</p><h5>Aetiology</h5><p>The aetiology is unknown <sup>1</sup>.</p><h5>Location</h5><p>Ectomesenchymomas have been described in the following locations <sup>1-5</sup>:</p><ul>
  • -<li>pelvis/perineum</li>
  • -<li>intraabdominal and retroperitoneum including urogenital organs</li>
  • -<li>head and neck region</li>
  • -<li>intracranial</li>
  • -</ul><p>Less commonly affected are the extremities and the mediastinum.</p><h5>Macroscopic appearance</h5><p>Tumours usually vary widely in size are multilobulated and encapsulated. They might show features of haemorrhage and/or necrosis and feature a tan to whitish appearance <sup>1</sup>.</p><h5>Microscopic appearance</h5><p>Ectomesenchymoma feature two histological components:</p><ul>
  • -<li>skeletal muscle component similar to <a href="/articles/embryonal-rhabdomyosarcoma">embryonal rhabdomyosarcoma</a>
  • +<p><strong>Ectomesenchymomas</strong> are biphasic or composite malignant <a href="/articles/who-classification-of-tumors-of-soft-tissue">soft tissue tumours</a> with rhabdomyosarcoma resembling parts and neuronal or neuroblastic features.</p><h4>Terminology</h4><p>The term ‘gangliorhabdomyosarcoma’ is not recommended anymore.</p><h4>Epidemiology</h4><p>Ectomesenchymomas are very rare and usually occur in infants and children ≤ 15 years with a slight male predominance <sup>1-3</sup>.</p><h4>Diagnosis</h4><p>The diagnosis of ectomesenchymoma is based on histology and <a href="/articles/immunohistochemistry" title="Immunohistochemistry">immunohistochemistry</a>.</p><h5>Diagnostic criteria</h5><p>Diagnostic criteria according to the <a href="/articles/who-classification-of-tumors-of-soft-tissue" title="WHO classification of soft tissue tumors">WHO classification of soft tissue and bone tumours (5<sup>th</sup> edition)</a> <sup>1</sup>:</p><ul>
  • +<li>
  • +<p>composite or intermixed histomorphology of two tumour components:</p>
  • +<ul>
  • +<li><p><a href="/articles/embryonal-rhabdomyosarcoma" title="Embryonal rhabdomyosarcoma">embryonal rhabdomyosarcoma</a> components</p></li>
  • +<li><p>neuroblastic tumour elements (<a href="/articles/neurone" title="Neurons">neurones</a>, <a href="/articles/ganglioneuroma" title="Ganglioneuroma">ganglioneuroma</a>, <a href="/articles/ganglioneuroblastoma" title="Ganglioneuroblastoma">ganglioneuroblastoma</a>, <a href="/articles/neuroblastoma" title="Neuroblastoma">neuroblastoma</a>)</p></li>
  • +</ul>
  • -<li>neuroectodermal components as <a href="/articles/ganglioneuroma">ganglioneuroma</a>, intermediate <a href="/articles/ganglioneuroblastoma">ganglioneuroblastoma</a> or primitive <a href="/articles/neuroblastoma">neuroblastoma</a>
  • -</li>
  • -</ul><h5>Immunophenotype</h5><p>Ectomesenchymoma is a multi phenotypic tumour and immunohistochemistry stains are usually positive for <a href="/articles/multiple-system-atrophy">muscle specific actin (MSA)</a>, <a href="/articles/desmin">desmin</a> and MYOD1 as well as <a href="/articles/neuron-specific-enolase">neuron specific enolase (NSE)</a> <a href="/articles/synaptophysin">synaptophysin</a>, <a href="/articles/chromogranin-a">chromogranin A</a> and <a href="/articles/s100">S100</a> <sup>1,2</sup>.</p><h4>Radiographic features</h4><p>Imaging findings seem to be a generally non-specific, heterogeneous mass <sup>4,5</sup>.</p><h5>MRI</h5><p>Magnetic resonance imaging features have been described as lobular, heterogeneous, partially cystic enhancing mass <sup>2,5</sup>.</p><h4>Radiology report</h4><p>The radiological report should include a description of the following:</p><ul>
  • -<li>form, location and size</li>
  • -<li>tumour margins and transition zone</li>
  • -<li>relations to other organs</li>
  • -<li>contact to bones or neurovascular structures</li>
  • -<li>associated lymphadenopathy</li>
  • -</ul><h4>Treatment and prognosis</h4><p>Treatment is usually multimodal and based on rhabdomyosarcoma-like management strategies. Superficial location, smaller tumour size and younger age ≤ 3years are favourable factors <sup>1,4</sup>.</p><h4>Differential diagnosis</h4><p>Conditions that can mimic the presentation and/or appearance of ectomesenchymomas also depend on the location of the tumour and include <sup>3-5</sup>:</p><ul>
  • -<li><a href="/articles/rhabdomyosarcoma">rhabdomyosarcoma</a></li>
  • -<li><a href="/articles/embryonal-rhabdomyosarcoma">embryonal rhabdomyosarcoma</a></li>
  • -<li><a href="/articles/neuroblastoma">neuroblastoma</a></li>
  • +<li><p>respective immune profile with reactivity to <a href="/articles/desmin" title="Desmin">desmin</a> and/or myogenin and <a href="/articles/synaptophysin" title="Synaptophysin">synaptophysin</a></p></li>
  • +</ul><h4>Clinical presentation</h4><p>The most common presentation is a superficial or deep soft tissue mass or an incidental finding on imaging studies <sup>1</sup>.  </p><h4>Pathology</h4><p>Ectomesenchymoma features a compound biphasic morphology with mesenchymal components resembling <a href="/articles/embryonal-rhabdomyosarcoma">embryonal rhabdomyosarcoma</a> and neuroectodermal or neuroblastic elements <sup>1-3</sup>.</p><h5>Aetiology</h5><p>The aetiology is unknown <sup>1</sup>.</p><h5>Location</h5><p>Ectomesenchymomas have been described in the following locations <sup>1-5</sup>:</p><ul>
  • +<li><p>pelvis/perineum</p></li>
  • +<li><p>intraabdominal and retroperitoneum including urogenital organs</p></li>
  • +<li><p>head and neck region</p></li>
  • +<li><p>intracranial</p></li>
  • +</ul><p>Less commonly affected are the extremities and the mediastinum.</p><h5>Macroscopic appearance</h5><p>Tumours usually vary widely in size and are multilobulated and encapsulated. They might show features of haemorrhage and/or necrosis and feature a tan to whitish appearance <sup>1</sup>.</p><h5>Microscopic appearance</h5><p>Ectomesenchymoma feature two histological components:</p><ul>
  • +<li><p>skeletal muscle component similar to <a href="/articles/embryonal-rhabdomyosarcoma">embryonal rhabdomyosarcoma</a></p></li>
  • +<li><p>neuroectodermal components as <a href="/articles/ganglioneuroma">ganglioneuroma</a>, intermediate <a href="/articles/ganglioneuroblastoma">ganglioneuroblastoma</a> or primitive <a href="/articles/neuroblastoma">neuroblastoma</a></p></li>
  • +</ul><h5>Immunophenotype</h5><p>Ectomesenchymoma is a multi-phenotypic tumour and immunohistochemistry stains are usually positive for <a href="/articles/multiple-system-atrophy">muscle-specific actin (MSA)</a>, <a href="/articles/desmin">desmin</a> and MYOD1 as well as <a href="/articles/neuron-specific-enolase">neurone-specific enolase (NSE)</a> <a href="/articles/synaptophysin">synaptophysin</a>, <a href="/articles/chromogranin-a">chromogranin A</a> and <a href="/articles/s100">S100</a> <sup>1,2</sup>.</p><h4>Radiographic features</h4><p>Imaging findings seem to be a generally non-specific, heterogeneous mass <sup>4,5</sup>.</p><h5>MRI</h5><p>Magnetic resonance imaging features are those of a lobular, heterogeneous, partially cystic-enhancing mass <sup>2,5</sup>.</p><h4>Radiology report</h4><p>The radiological report should include a description of the following:</p><ul>
  • +<li><p>form, location and size</p></li>
  • +<li><p>tumour margins and transition zone</p></li>
  • +<li><p>relations to other organs</p></li>
  • +<li><p>contact to bones or neurovascular structures</p></li>
  • +<li><p>associated lymphadenopathy</p></li>
  • +</ul><h4>Treatment and prognosis</h4><p>Treatment is usually multimodal and based on rhabdomyosarcoma-like management strategies: superficial location, smaller tumour size and younger age ≤3 years are favourable factors <sup>1,4</sup>.</p><h4>History and etymology</h4><p>Initial suggestions regarding the entity ectomesenchymoma were probably made by the American pathologists <strong>Samruay Shuangshoti</strong> and <strong>Martin G Netsky</strong> as well as<strong> James L. Holimon</strong> and <strong>William I. Rosenblum</strong> in 1971 <sup>6,7</sup>.</p><h4>Differential diagnosis</h4><p>Conditions that can mimic the presentation and appearance of ectomesenchymomas also depend on the location of the tumour and include <sup>3-5</sup>:</p><ul>
  • +<li><p><a href="/articles/rhabdomyosarcoma">rhabdomyosarcoma</a></p></li>
  • +<li><p><a href="/articles/embryonal-rhabdomyosarcoma">embryonal rhabdomyosarcoma</a></p></li>
  • +<li><p><a href="/articles/neuroblastoma">neuroblastoma</a></p></li>

References changed:

  • 1. Huang SC, Antonescu CR. Ectomesnchymoma. In: WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 5th ed.; vol. 3). <a href="https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Soft-Tissue-And-Bone-Tumours-2020">https://publications.iarc.fr</a>
  • 6. Shuangshoti S & Netsky M. Neoplasms of Mixed Mesenchymal and Neuroepithelial Origin. Relation to "Monstrocellular Sarcoma" or "Giant-Celled Glioblastoma". J Neuropathol Exp Neurol. 1971;30(2):290-309. <a href="https://doi.org/10.1097/00005072-197104000-00010">doi:10.1097/00005072-197104000-00010</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/4947980">Pubmed</a>
  • 7. Holimon J & Rosenblum W. "Gangliorhabdomyosarcoma": A Tumor of Ectomesenchyme. Case Report. J Neurosurg. 1971;34(3):417-22. <a href="https://doi.org/10.3171/jns.1971.34.3.0417">doi:10.3171/jns.1971.34.3.0417</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/5313338">Pubmed</a>
  • 1. W. H. O. Classification WHO Classification of Tumours Editorial Board, Who Classification of Tumours Editorial. Soft Tissue and Bone Tumours. (2020-04-17) ISBN: 9789283245025

Tags changed:

  • cases3
  • soft tissue tumours

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.